LPL Financial LLC Sells 94,324 Shares of Tilray Inc (NASDAQ:TLRY)

LPL Financial LLC lowered its holdings in shares of Tilray Inc (NASDAQ:TLRY) by 31.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 208,793 shares of the company’s stock after selling 94,324 shares during the period. LPL Financial LLC’s holdings in Tilray were worth $278,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Verdence Capital Advisors LLC bought a new position in shares of Tilray during the fourth quarter valued at $29,000. Ameritas Advisory Services LLC bought a new position in shares of Tilray during the fourth quarter valued at $32,000. Newman Dignan & Sheerar Inc. raised its stake in shares of Tilray by 61.9% during the fourth quarter. Newman Dignan & Sheerar Inc. now owns 26,150 shares of the company’s stock valued at $35,000 after acquiring an additional 10,000 shares during the last quarter. Brooklyn FI LLC bought a new position in shares of Tilray during the fourth quarter valued at $36,000. Finally, Jones Financial Companies Lllp raised its stake in shares of Tilray by 125.7% during the fourth quarter. Jones Financial Companies Lllp now owns 31,725 shares of the company’s stock valued at $42,000 after acquiring an additional 17,670 shares during the last quarter. Institutional investors own 9.35% of the company’s stock.

Tilray Trading Down 2.1 %

NASDAQ:TLRY opened at $0.48 on Tuesday. The company has a current ratio of 2.54, a quick ratio of 1.58 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $480.00 million, a price-to-earnings ratio of -1.59 and a beta of 1.88. The firm has a fifty day simple moving average of $0.62 and a two-hundred day simple moving average of $1.07. Tilray Inc has a 12 month low of $0.43 and a 12 month high of $2.52.

Tilray (NASDAQ:TLRY) last posted its quarterly earnings results on Tuesday, April 8th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.06). The company had revenue of $185.78 million during the quarter, compared to analyst estimates of $213.38 million. Tilray had a negative return on equity of 4.40% and a negative net margin of 30.95%. Analysts expect that Tilray Inc will post -0.2 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Piper Sandler decreased their price objective on shares of Tilray from $2.00 to $1.00 and set a “neutral” rating for the company in a research report on Wednesday, April 9th. Canaccord Genuity Group increased their price objective on shares of Tilray from $2.00 to $3.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Finally, Roth Capital reiterated a “neutral” rating on shares of Tilray in a research report on Monday, April 14th.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.